157 related articles for article (PubMed ID: 19549221)
1. Caspofungin for the treatment of candidaemia in patients with haematological malignancies.
Pagano L; Fianchi L; Fanci R; Candoni A; Caira M; Posteraro B; Morselli M; Valentini CG; Farina G; Mitra ME; Offidani M; Sanguinetti M; Tosti ME; Nosari A; Leone G; Viale P
Clin Microbiol Infect; 2010 Mar; 16(3):298-301. PubMed ID: 19549221
[TBL] [Abstract][Full Text] [Related]
2. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study.
Sipsas NV; Lewis RE; Raad II; Kontoyiannis DP
Int J Antimicrob Agents; 2009 Jul; 34(1):95-8. PubMed ID: 19251404
[TBL] [Abstract][Full Text] [Related]
3. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
4. Candida krusei--a serious complication in patients with hematological malignancies: successful treatment with caspofungin.
Conen A; Weisser M; Jörg CO; Battegay M; Trampuz A; Frei R; Christen S; Heim D; Gratwohl A; Flückiger U
Transpl Infect Dis; 2008 Feb; 10(1):66-70. PubMed ID: 17511816
[TBL] [Abstract][Full Text] [Related]
5. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
6. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin for the treatment of less common forms of invasive candidiasis.
Cornely OA; Lasso M; Betts R; Klimko N; Vazquez J; Dobb G; Velez J; Williams-Diaz A; Lipka J; Taylor A; Sable C; Kartsonis N
J Antimicrob Chemother; 2007 Aug; 60(2):363-9. PubMed ID: 17526917
[TBL] [Abstract][Full Text] [Related]
8. Saprochaete capitata as an emerging fungus among patients with haematological malignencies.
Ulu-Kilic A; Atalay MA; Metan G; Cevahir F; Koç N; Eser B; Çetin M; Kaynar L; Alp E
Mycoses; 2015 Aug; 58(8):491-7. PubMed ID: 26155743
[TBL] [Abstract][Full Text] [Related]
9. A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland.
Anttila VJ; Salonen J; Ylipalosaari P; Koivula I; Riikonen P; Nikoskelainen J
Clin Microbiol Infect; 2007 Jun; 13(6):606-12. PubMed ID: 17378926
[TBL] [Abstract][Full Text] [Related]
10. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
12. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
Viscoli C; Herbrecht R; Akan H; Baila L; Sonet A; Gallamini A; Giagounidis A; Marchetti O; Martino R; Meert L; Paesmans M; Ameye L; Shivaprakash M; Ullmann AJ; Maertens J;
J Antimicrob Chemother; 2009 Dec; 64(6):1274-81. PubMed ID: 19841031
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
Lichtenstern C; Nguyen TH; Schemmer P; Hoppe-Tichy T; Weigand MA
Mycoses; 2008; 51 Suppl 1():35-46. PubMed ID: 18471160
[TBL] [Abstract][Full Text] [Related]
16. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints.
Gamaletsou MN; Daikos GL; Walsh TJ; Perlin DS; Ortigosa CJ; Psaroulaki A; Pagoni M; Argyropoulou A; Nepka M; Perivolioti E; Kotsopoulou M; Perloretzou S; Marangos M; Kofteridis D; Grammatikou M; Goukos D; Petrikkos G; Sipsas NV
Int J Antimicrob Agents; 2014 Sep; 44(3):248-55. PubMed ID: 25108876
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and outcome for breakthrough candidaemia in patients with cancer.
Chung JW; Lee SO; Choi SH; Woo JH; Ryu J; Kim YS; Kim NJ
Mycoses; 2006 Mar; 49(2):114-8. PubMed ID: 16466444
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin.
Bayramoglu G; Sonmez M; Tosun I; Aydin K; Aydin F
Infection; 2008 Feb; 36(1):68-70. PubMed ID: 17882360
[TBL] [Abstract][Full Text] [Related]
20. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.
Blanchard E; Lortholary O; Boukris-Sitbon K; Desnos-Ollivier M; Dromer F; Guillemot D;
Antimicrob Agents Chemother; 2011 Nov; 55(11):5358-61. PubMed ID: 21859944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]